Bioequivalence study of 50 mg Diclofenac Sodium Enteric Coated Tablets Manufactured by PT. Samco Farma (SAMCOFENAC 50) In Comparison With The Innovator’s Enteric Coated Tablets (Voltaren 50) Manufactured by PT. Novartis Indonesia, Jakarta, Indonesia, Under License of Novartis Pharma AG Basel, Switzerland
Tahapan Penelitian : Complete
Sponsor:
PT. Samco Farma
Mitra Pelaksana:
Econolab
No Registry
INA-SDZMO78
Tanggal Input Registry : 09-02-2024
| Tracking Information | |
|---|---|
| Tanggal Antisipasi Studi | 12-01-2019 |
| Outcome Primer | AUC-t and Cmax |
| Outcome Skunder | AUC0-t, Tmax, T1/2 |
| Descriptive Information | |
| Judul Penelitian Popular | Bioequivalence study of 50 mg Diclofenac Sodium Enteric Coated Tablets Manufactured by PT. Samco Farma (SAMCOFENAC 50) In Comparison With The Innovator’s Enteric Coated Tablets (Voltaren 50) Manufactured by PT. Novartis Indonesia, Jakarta, Indonesia, Under License of Novartis Pharma AG Basel, Switzerland |
| Judul Penelitian Ilmiah | Bioequivalence study of 50 mg Diclofenac Sodium Enteric Coated Tablets Manufactured by PT. Samco Farma (SAMCOFENAC 50) In Comparison With The Innovator’s Enteric Coated Tablets (Voltaren 50) Manufactured by PT. Novartis Indonesia, Jakarta, Indonesia, Under License of Novartis Pharma AG Basel, Switzerland |
| Jenis Penelitian | Interventional |
| Intervensi | Single dose of one enteric coated tablet of 100 mg Sildenafil (SAMCOFENAC®50), Manufactured pt Samco Farma |
| Jumlah Subyek Penelitian | 26 |
| Recruitment Information | |
| Eligibility Criteria | Inclusion Criteria: Healthy male/female subjects determined by the medical screening assessments; Aged 18-55 years of age; Body mass index is in the range of 18-25 kg/m²; Systolic blood pressure :100-120 mmHg; Diastolic blood pressure : 60-80 mmHg; Pulse rate 60-90 bpm; Normal ECG; Able to communicate well with the investigators and sign an informed consent; Clinical laboratory results have to be within normal range.Exclusion Criteria: Pregnant or lactating women (urinary pregnancy test were applied to female subjects when screening and just before taking the test or innovator drug); Known hypersensitivity or contraindication to the study drug; intake of any prescription drug or non-prescription drug/food supplement/herbal medicine within 7 days of this study’s first dosing day; History of any bleeding or coagulation disorders; Any surgical or medical condition (present or history) which might significantly alters the absorption, distribution, metabolism or excretion of the study drug, e.g. gastrointestinal diseases including gastric or duodenal ulcers or history of gastric surgery; A donation or loss of 450 mL (or more) of blood within 3 months before this study’s first dosing day; A positive Hepatitis B surface antigen (HBsAg), HCV, HIV test result; History of drug or alcohol abuse within 12 months prior to this study; Heavy Smoker (more than 10 cigarettes a day); Clinically have significant bleeding within 3 months prior to the study; Participation in a previous study within 3 months of this study’s first dosing day. |
| Administrative Information | |
| Nomor Persetujuan Etik | 0904/UN2.F1/ETIK/2018 |
| Nomor Persetujuan Material Transfer Agreement | Not applicable |
| Nomor Persetujuan Pelaksanaan Uji Klinik | PPUK/PPUB number |
| Other Study ID Numbers | PRO-223/19/ECL |
| Contact Person | Ni Made Dwi Wulandari |